Literature DB >> 20505556

Association of DISC1 gene with schizophrenia in families from two distinct French and Algerian populations.

Aude-Marie Lepagnol-Bestel1, Caroline Dubertret, Dalila Benmessaoud, Michel Simonneau, Jean Adès, Farid Kacha, Nora Hamdani, Philip Gorwood, Nicolas Ramoz.   

Abstract

OBJECTIVE: The Disrupted-in-Schizophrenia-1 (DISC1) gene is a promising genetic risk factor for major mental illnesses, especially schizophrenia. Several variants encompassing the DISC1 gene have been associated with schizophrenia and specific clinical features. Negative results were nevertheless observed, stratification biases, heterogeneity of the analyzed samples and low statistical power being potentially involved.
METHODS: We analyzed four single nucleotide polymorphisms (SNPs), including three non-synonymous SNPs, of DISC1 in two independent samples of trios, from France and Algeria, using family-based association tests to elude statistical limits.
RESULTS: In 114 French schizophrenia trios, the C allele of non-synonymous rs6675281/Leu607Phe/C1872T was significantly over-transmitted [odds ratio (OR)=2.3, 95% confidence interval (CI)=1.1-4.4]. This same SNP was also more frequently transmitted in the 100 Algerian schizophrenia trios (OR=2.6, 95% CI=0.9-7.3). In the combined 214 trios, a significant over-transmission of the C allele of rs6675281 to the affected probands was observed (P=0.002), even after correction for multiple testing (P corrected=0.01 OR=2.4 and 95% CI=1.3-4.2). Assessing if a dimension of schizophrenia could be more specifically involved, we found that patients with the C allele had a significantly higher Scale for the Assessment of Negative Symptoms total score (P=0.0002).
CONCLUSION: The analysis adds convergent evidence in favor of a significant role of the DISC1 gene as a risk factor for schizophrenia, as present in two different samples, in family trios rather than with a case--control approach, and even when multiple tests are controlled for. We could further potentially attribute this effect to the negative dimension of schizophrenia.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20505556     DOI: 10.1097/YPG.0b013e32833aa5c4

Source DB:  PubMed          Journal:  Psychiatr Genet        ISSN: 0955-8829            Impact factor:   2.458


  6 in total

Review 1.  Personalized medicine in psychiatry: problems and promises.

Authors:  Uzoezi Ozomaro; Claes Wahlestedt; Charles B Nemeroff
Journal:  BMC Med       Date:  2013-05-16       Impact factor: 8.775

2.  DISC1 variants 37W and 607F disrupt its nuclear targeting and regulatory role in ATF4-mediated transcription.

Authors:  Elise L V Malavasi; Fumiaki Ogawa; David J Porteous; J Kirsty Millar
Journal:  Hum Mol Genet       Date:  2012-03-15       Impact factor: 6.150

Review 3.  DISC1-binding proteins in neural development, signalling and schizophrenia.

Authors:  Nicholas J Bradshaw; David J Porteous
Journal:  Neuropharmacology       Date:  2010-12-31       Impact factor: 5.250

4.  Disrupted-in-schizophrenia 1 functional polymorphisms and D2 /D3 receptor availability: A [11 C]-(+)-PHNO imaging study.

Authors:  Tarik Dahoun; Matthew M Nour; Rick A Adams; Svenja Trossbach; Sang H Lee; Hamel Patel; Charles Curtis; Carsten Korth; Oliver D Howes
Journal:  Genes Brain Behav       Date:  2019-07-05       Impact factor: 3.708

5.  Functional properties of rare missense variants of human CDH13 found in adult attention deficit/hyperactivity disorder (ADHD) patients.

Authors:  Thegna Mavroconstanti; Stefan Johansson; Ingeborg Winge; Per M Knappskog; Jan Haavik
Journal:  PLoS One       Date:  2013-08-01       Impact factor: 3.240

6.  Association analysis of DISC1 gene polymorphisms with Attention-Deficit Hyperactivity Disorder in Iranian population.

Authors:  Matin Kayyal; Abolfazl Movafagh; Mehrdad Hashemi; Arezou Sayad; Babak Emamalizadeh; Khashayar PourIran; Mohammadmoien Kayyal; Mohammad Reza Eslami Amirabadi; Mahdi Zamani; Hossein Darvish
Journal:  Pak J Med Sci       Date:  2015 Sep-Oct       Impact factor: 1.088

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.